Literature DB >> 17715045

[Expression of heparanase and nuclear factor kappa B in pancreatic adenocarcinoma].

Wu-Jun Wu1, Cheng-En Pan, Qing-Guang Liu, Ke-Wei Meng, Hai-Bo Yu, You-Li Wang, Lin Zhao.   

Abstract

OBJECTIVE: To detect the expressions of heparanase and nuclear factor kappa B p65 (NF-kappaB p65) in pancreatic adenocarcinomas and analyze their relation to patients' prognosis and the regulatory mechanism of NF-kappaB on heparanase expression.
METHODS: Heparanase and NF-kappaB p65 proteins in the tumor and adjacent tissues were detected by immunohistochemistry in 48 patients with pancreatic adenocarcinoma and analyzed for their clinicopathological significance.
RESULTS: Heparanase and NF-kappaB p65 proteins were found in 30 (62.5%) and 22 (45.9%) tumor specimens, respectively, a rate significantly higher than that in the adjacent tissues. High heparanase expression was closely related to advanced TNM stage (P=0.031), lymph node metastasis (P=0.003) and decreased 3-year postoperative survival (20.0% vs 0%, P=0.001). NF-kappaB p65 expression was associated with lymph node metastasis (P=0.017) and distant metastasis (P=0.031), but had a higher positive rate in heparanase-positive cases than in heparanase-negative cases (P=0.018). Multivariate analysis showed that neither heparanase nor NF-kappaB p65 was the independent prognostic factors.
CONCLUSION: Heparanase is overexpressed in pancreatic adenocarcinomas in association with decreased postoperative survival. NF-kappaB may up-regulate heparanase expression and promote heparanase-dependent tumor invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715045

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  1 in total

1.  Oligomannurarate sulfate blocks tumor growth by inhibiting NF-kappaB activation.

Authors:  Jing Zhang; Yi Chen; Xian-liang Xin; Qiu-ning Li; Ming Li; Li-ping Lin; Mei-yu Geng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2010-02-15       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.